EU/3/09/683 - orphan designation for treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid

cholic acid

Overview

On 28 October 2009, orphan designation (EU/3/09/683) was granted by the European Commission to Special Products Ltd, United Kingdom, for cholic acid for the treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid.

The sponsorship was transferred to Retrophin Europe Limited, Ireland, in May 2015.

Cholic acid was authorised in the EU as Kolbam on 20 November 2015.

The marketing authorisation was withdrawn on 15 July 2020.

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products by the European Commission in July 2020 at the time of withdrawal of the marketing authorisation.

What are inborn errors in primary bile acid synthesis?

Inborn errors in primary bile acid synthesis are a group of diseases in which the liver does not produce ('synthesise') enough 'primary bile acids'. These acids are the main components of the bile, a fluid that helps digestion, and include cholic acid and chenodeoxycholic acid. The lack of bile acids is caused by inborn genetic abnormalities.

Patients lacking primary bile acids produce abnormal bile acids instead. These acids can damage the liver. In some cases, this can lead to liver failure. Not all errors in primary bile acid synthesis can be treated with cholic acid. Therefore, patients with these conditions can be divided into two groups, depending on whether they are responsive to treatment with cholic acid or not.

Inborn errors in primary bile acid synthesis responsive to treatment with cholic acid are a group of long-term debilitating and life-threatening diseases because they can severely damage the liver.

What is the estimated number of patients affected by the condition?

At the time of designation, inborn errors in primary bile acid synthesis responsive to treatment with cholic acid affected approximately 0.07 in 10,000 people in the European Union (EU). This was equivalent to a total of around 3,500 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. At the time of designation, this represented a population of 504,800,000 (Eurostat 2009).

What treatments are available?

At the time of designation, no satisfactory methods were authorised in the EU for the treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid. Patients with severe liver disease may need a liver transplant. Chenodeoxycholic acid and another bile acid called ursodeoxycholic acid, although authorised for other conditions, were used to treat inborn errors in primary bile acid synthesis.

How is this medicine expected to work?

Cholic acid is expected to work by replacing some of the missing bile acids in patients with inborn errors in primary bile acid synthesis. This is expected to decrease the production of abnormal bile acids and contribute to the normal activity of bile acids, therefore relieving the symptoms of these diseases.

What is the stage of development of this medicine?

The sponsor of this application has not conducted any studies with cholic acid. However, it provided the results of studies on the effects of cholic acid in experimental models and of clinical trials from the published literature to support its application for orphan designation.

At the time of submission, cholic acid was not authorised anywhere in the EU for inborn errors in primary bile acid synthesis responsive to treatment with cholic acid. Orphan designation of cholic acid had been granted in the EU and the United States of America for inborn errors in primary bile acid synthesis.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 2 September 2009 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the Community) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/09/683: Public summary of positive opinion for orphan designation of cholic acid for the treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid

AdoptedReference Number: EMEA/COMP/590369/2009 Rev.5

Key facts

• Active substance:
  cholic acid
• Medicine name:
  Kolbam
• Intended use:
  Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid
• Orphan designation status:
  Withdrawn
• EU designation number:
  EU/3/09/683
• Date of designation:
  29/10/2009
• Sponsor:

  Retrophin Europe Limited; 2nd Floor Palmerston House; Fenian Street; Dublin 2; Ireland; Tel. [phone]; E-mail : [e-mail]

Review of designation

During its meeting of 6 to 8 October 2015, the Committee for Orphan Medicinal Products (COMP) reviewed the designation EU/3/09/683 for Kolbam (cholic acid)as an orphan medicinal product for the treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid. The COMP assessed whether, at the time of marketing authorisation, the medicinal product still met the criteria for orphan designation. The Committee looked at the seriousness and prevalence of the condition, and the existence of other methods of treatment. As other methods of treatment for patients with this condition are authorised in the European Union (EU), the COMP also looked at the significant benefit of the product over existing treatments. The COMP recommended that the orphan designation of the medicine be maintained¹.

---

¹The maintenance of the orphan designation at time of marketing authorisation would, except in specific situations, give an orphan medicinal product 10 years of market exclusivity in the EU. This means that in the 10 years after its authorisation similar products with a comparable therapeutic indication cannot be placed on the market.